• Sign up to our Free Newsletter
  • Contact Us
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Editor’s Choice

Editor's Choice

A microbiome therapeutic is closer than ever to market authorization in the US. What does it mean for the industry?

September 28, 2022 Kristina Campbell

Ferring Pharmaceuticals, Inc. has edged ahead in the race to bring the first microbiome-based drug to market in the United States, with its product REBYOTA receiving the thumbs up from the FDA’s Vaccines and Related […]

Editor's Choice

Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660

September 23, 2022 Microbiome Times

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) issued a positive vote for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential […]

Editor's Choice

Stanford researchers construct most complex, complete synthetic microbiome

September 9, 2022 Microbiome Times

Key studies in the last decade have shown that the gut microbiome, the collection of hundreds of bacterial species that live in the human digestive system, influences neural development, response to cancer immunotherapies, and other […]

Editor's Choice

Fecal Microbiota Transplantation (FMT): Global Industry and Regulatory Overview

June 27, 2022 Luis Gosálbez

First described in the 4th Century in China, practiced since the 1950’s and re-discovered relatively recently [1][2], Fecal Microbiota Transplantation (FMT) or simply Fecal Transplant is a therapeutic approach in which more or less processed […]

Editor's Choice

Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers

April 15, 2022 Laurence Zitvogel

 

Editor's Choice

Did you miss Probiota Copenhagen 2022? Catch up now!

April 12, 2022 Nina Vinot

With 400 registered and 60 people on the waiting list, this edition of Probiota, the first in-person since 2020, broke all records. The event started with the best and only way it is meant to: […]

Editor's Choice

A new strategy for editing DNA within microbial communities using CRISPR-Cas9 technology

February 18, 2022 Kristina Campbell

Benjamin Rubin was a post-doc in the lab of Jennifer Doudna—a Nobel-prize-winning scientist who pioneered CRISPR-Cas9—when a colleague got him thinking about a microbial ecology problem. He started to wonder: could it be possible to […]

Biotech Showcase

Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132

February 17, 2022 Jean de Gunzburg

  This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 […]

Editor's Choice

ELIGO v SNIPR: a reflection on IP strategies in a competitive environment

February 7, 2022 Craig Thomson and Jennifer Bailey

Introduction In November 2021, US “Interference” proceedings resulted in cancellation of five US patents owned by SNIPR TECHNOLOGIES. It was concluded that the technology claimed in those patents was invented earlier by The Rockefeller University.  […]

Editor's Choice

Ferring takes pre-emptive action in IP dispute with Finch

February 2, 2022 Kristina Campbell

In the relatively young microbiome biotechnology industry, companies aim to distinguish themselves from a growing number of competitors by protecting their intellectual property (IP). As in any new field, initial patent claims tend to be […]

Editor's Choice

Food for Health: A new direction for American Agriculture

December 14, 2021 Andrew Benson and Bruce German

Over the past two years during this global pandemic, it has become clear that regrettably, those of us who are the most vulnerable to severe disease from SARS-CoV-2 are the ones with underlying chronic diseases […]

Posts navigation

« 1 2 3 … 11 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • Microbiome drug development: Analysis of the historical pipeline reveals promising areas and bottlenecks
    May 25, 2023
  • DNA Genotek enables development of microbiome-based clinical applications with OMNIgene™•GUT Dx – the first and only FDA-authorized fecal self-collection device
    May 10, 2023
  • Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™
    April 27, 2023
  • Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
    April 25, 2023
  • Researchers create virus-resistant, safely restrained E. coli
    April 10, 2023
sign up

Sign up to the Microbiome Times newsletter